Next-Generation Predictive Models for Drug Discovery, Pharmacology, and Toxicology
📅 Deadline: February 28, 2027
📚 Journal URL: Majestic Journal of Pharmacology and Toxicology
Thematic Issue Guest Editor
Dr. Jie Huang
Lead Guest Editor
President at American Association for Scientist Entrepreneurship (AASE)
Chief Scientist and CEO at CSTEAM Biotechnology USA
Dr. Jie Huang is an internationally recognized scientist, entrepreneur, and biotechnology leader specializing in translational medicine, cell and gene therapy, biotechnology innovation, and AI-enabled healthcare solutions. He serves as President of the American Association for Scientist Entrepreneurship (AASE), Editor-in-Chief of Lab-to-Startup Review, and Founder, CEO, and Chief Scientist of CSTEAM Biotechnology, USA. His research focuses on immunology, oncology, regenerative medicine, CAR-T and CAR-NK therapies, precision medicine, and AI-driven drug discovery. He has authored numerous scientific publications and holds over 30 patents in biotechnology and biomedical innovation. Dr. Huang is an active member of JSI, JCA, AACR, ASCO, and ASGCT, and serves as Principal Investigator of the Single-Cell and Microenvironment Research Program within the Human Cell Atlas (HCA) initiative.
Dr. Ju Guo
Associate Professor, School of Management, Chengdu University of Information Technology, China
Dr. Ju Guo is an Associate Professor at the School of Management, Chengdu University of Information Technology, China. Her research focuses on organizational behavior, human resource management, management psychology and behavior, organizational digitization, and innovation and entrepreneurship. She has published nearly 10 SSCI articles as first author in journals such as Managerial and Decision Economics, Current Psychology, Journal of Child and Family Studies. She also serves as an anonymous reviewer for several SSCI journals.
Aim and Scope of the Thematic Issue
The development of predictive and human-relevant experimental systems is reshaping modern pharmacology and toxicology. Traditional preclinical models frequently fail to accurately predict human therapeutic efficacy, toxicity, and translational outcomes, contributing to high clinical failure rates and increasing development costs. Consequently, there is growing interest in next-generation predictive technologies capable of improving translational reliability and accelerating safer drug development.
This thematic issue aims to highlight emerging interdisciplinary approaches that are transforming drug discovery, pharmacological evaluation, and toxicological assessment. The issue will cover organoids, organ-on-chip systems, microphysiological platforms, AI-assisted pharmacology, computational toxicology, spatial and single-cell technologies, translational bioengineering, predictive biomarkers, exosome-based therapeutics, and advanced humanized disease models.
Particular emphasis will also be placed on translational and regulatory perspectives, including New Approach Methodologies (NAMs), alternatives to animal testing, precision medicine frameworks, and predictive systems for evaluating therapeutic efficacy and safety. Both original research articles and comprehensive review papers will be welcomed.
Recommended Topics/Sub-themes:
- AI-driven predictive pharmacology
- Computational toxicology
- Organoid and organ-on-chip systems
- Human-relevant disease models
- Precision pharmacology and personalized medicine
- Exosome-based therapeutics
- Translational bioengineering platforms
- Spatial biology and single-cell pharmacology
- Predictive biomarker development
- Cell and gene therapy evaluation models
- FDA NAMs-related technologies
- Alternatives to animal testing
- Multi-omics platforms in drug development
- Safety evaluation of advanced therapeutics
Potential Contributors and Collaborators:
Potential contributors may include researchers, clinicians, translational scientists, and biotechnology professionals working in pharmacology, toxicology, organoid technologies, AI-assisted drug discovery, cell and gene therapy, computational biology, translational medicine, and bioengineering.
Submission Process and Guidelines
Authors are invited to submit original research and review articles that align with the theme of this special issue and must comply with MJPT author guidelines. Authors should submit their manuscripts via the journal’s Online Journal System (OJS) at https://ma-pharmacology.cmpublisher.com/index.php/ojs/login
Note: All submissions must include a cover letter stating the name of the thematic issue and Author details. All papers will undergo a double-blind peer review process according to MJPT editorial standards to ensure high-quality contributions.
Publication Fee: No submission fees or article processing charges apply to this thematic issue.
Important Dates
- Call for Papers Release: September 2026
- Manuscript Submission Deadline: February 30, 2027
- First Round Peer Review Completion: April 2027
- Revised Manuscript Submission: May 2027
- Final Acceptance: June 2027
- Online Publication: July–August 2027
Contact Information
For editorial or any inquiries regarding this special issue, please contact:
Ms. Grace Mitchell
Editorial Manager
Majestic Journal of Pharmacology and Toxicology (MJPT)
Email: gracemitchell.pharma@cmpublisher.com, ma-pharmacology@cmpublisher.com
No issues articles found.